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EditorialEmerging trends in hepatology: 30 years of the Journal of
Hepatology and 50 years of EASL
Rajiv Jalan⇑,
Institute for Liver and Digestive Health, UCL Medical School, Royal Free Hospital Campus, Rowland Hill Street, London NW3 2PF, United KingdomThe availability of drugs that can cure hepatitis C virus infection
provides a wonderful backdrop for the Journal of Hepatology to
start its 31st year. It is clear to us all that the landscape of
Hepatology will change within the next 10 years and therefore
it is very exciting to introduce this supplement. Despite this pro-
gress, deaths from liver disease are occurring at a staggering rate
(Table 1) [1] and the beneﬁts of the hepatitis C drugs in reducing
death rates will take many years. The main culprits of the
increasing burden of disease, non-alcoholic fatty liver disease
(NAFLD) and alcohol related liver disease, need to be tackled at
a societal and political level. The immediate cause of death in
these patients, liver failure and liver cancer require better
biomarkers and new therapies for earlier diagnosis and treat-
ment. This supplement is a collection of awe-inspiring, inspira-
tional and must-read articles of exceptional quality written by
the world leaders in their own ﬁelds, often collaborating across
continents to bring together this celebratory issue. The articles
not only provide the best current evidence and insights into what
the future holds for hepatology but also highlight how we have
got to this point.
Karlsen, Lammert, and Thompson combine their huge
knowledge base into focusing on our current understanding of
how genetics is helping us better understand the pathogenesis
of liver disease. They extend their article to describe how genetics
is being used to identify the cause of hereditary liver diseases and
allowing predictions about susceptibility to complex diseases and
their re-classiﬁcation. They extend their paper to highlight that
genetic studies suggests new modes of treatment of diseases.
Finally, they look a little into the future to deﬁne how using geno-
mics may help to customize the management of the individual
patient.
Hepatic ﬁbrosis underlies the occurrence of chronicity of liver
disease. Trautwein, Friedman, Schuppan, and Pinzani combine
their immense knowledge and huge scientiﬁc enterprise to pro-
vide an understanding of the current knowledge of the condition
and provide insights into how close we may be in ﬁnding a ‘true’
anti-ﬁbrotic. Given the relatively long timelines in the evolution
of ﬁbrosis, drug development is challenging. They highlight these
potential difﬁculties and describe some of the many efforts that
are being put into place to allow an adequate regulatory environ-
ment for drug development.Journal of Hepatology 20
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 The author is Editor-in-Chief of the Journal of Hepatology.Those who are mad from bile are vociferous, malignant and will
not be quiet. Hippocrates, 5th century BC. Beuers, Trauner, Jansen,
and Poupon have dedicated their lives in trying to understand
the underlying mechanisms of cholestasis. They masterfully turn
an extremely complex area of Hepatology into an absolute
delight to read. They highlight that the complex molecular
mechanisms that are involved in the pathogenesis of cholestasis
are now possible to target. There are real novel targets of therapy;
the farsenoid X receptor pathway and the pregnane X receptor
pathway. The clinical and pathophysiological effects of targeting
these receptors are pleiotropic and have potential beneﬁcial
effects in many types of liver disease patients.
Alcohol, of course, is a huge and growing problem throughout
the world and deaths from alcohol related liver disease is increas-
ing worldwide at an alarming rate. Unfortunately, therapeutic
advances in the management of alcoholic hepatitis have been
limited to steroids since the 1980s. Mathurin and Bataller,
combine their expertise in clinical, translational and basic
research to describe the massive advance there has been in the
ﬁeld of alcohol related liver disease and point to how newmodels
of care, standardization of management protocols and access
to novel therapeutic agents will change the landscape. They
also tackle the very thorny and widely debated issue of
transplantation of patients with alcoholic hepatitis in a very
balanced manner.
NAFLD is fast becoming the main cause of increase in the
prevalence of liver disease not only in the Western countries
but also in China, and urgent solutions for this condition are
needed. Byrne and Targher, who are well known experts in the
ﬁeld highlight the rapidly expanding body of clinical evidence
that supports the concept that NAFLD is a multisystem disease.
They describe factors linking NAFLD with other extrahepatic
chronic diseases, such as diabetes, coronary artery disease and
chronic kidney disease, placing an urgent need to develop new
drugs for its treatment. Ratziu, Goodman, and Sanyal, who are
leading a large NAFLD consortia on either side of the Atlantic,
indicate that the treatment of NAFLD is an unmet need. Their
deep understanding of the issues of NAFLD treatment is reﬂected
in their approach to analyzing why we do not have a drug to treat
the condition yet and why we are now in an incredibly exciting
phase where testing new interventions would be easier. They
then provide an in-depth look at the different approaches that
are being developed and predict what we may expect in the near
future.15 vol. 62 j S1–S3
Table 1. Global deaths related to liver disease in 2013 for all ages and both
sexes, with change since 1990 expressed in absolute terms and as a
percentage change in median estimate over the time period. (Data kindly
provided by Benjamin Cowie).
2013 Estimate Change 
1990-2013
% Change 
1990-2013
Acute hepatitis infection 136,657 -25,327 -15.6%
Acute HAV 14,912 -7724 -34.1%
Acute HBV 68,642 -16,349 -19.2%
Acute HCV 3451 +1154 +50.2%
Acute HEV 49,652 -2409 -4.6%
Liver cancer 817,969 +307,911 +60.4%
Liver cancer due to HBV 300,003 +101,649 +51.2%
Liver cancer due to HCV 342,530 +255,083 +291.7%
Liver cancer due to 
alcohol
92,159 -30,638 -25.0%
Liver cancer due to other 
causes
83,278 -18,183 -17.9%
Cirrhosis 1,221,129 +383,133 +45.7%
Cirrhosis due to HBV 317,384 +83,487 +35.7%
Cirrhosis due to HCV 357,807 +144,738 +67.9%
Cirrhosis due to alcohol 383,797 +91,551 +31.3%
Cirrhosis due to other 
causes
162,142 +63,357 +64.1%
Total HBV related 686,029 +168,787 +32.6%
Total HCV related 703,788 +400,975 +132.4%
Total viral hepatitis related 1,454,381 +559,630 +62.5%
Total alcohol related 475,956 +60,913 +14.7%
Total other liver disease 
related
245,420 +45,174 +22.6%
Total liver disease 2,175,755 +665,717 +44.1%
EditorialThe story of hepatitis C by Pawlotsky, Feld, Zeuzem, and
Hoofnagle, is probably the most inspirational I have read for a
long time; a story that every liver trainee should read and all liver
disease experts would like to be able to write about regarding
their own areas some time in their life. They start at the begin-
ning and highlight how we have arrived at a cure for this nasty
disease. They then discuss the challenges that face us in imple-
menting the treatment of hepatitis C. To quote the authors ‘It is
the story of this adventure, from discovery to cure, that we
are telling here’. A part of the challenge that faces hepatitis C is
already being faced by hepatitis B, that has been battling the
challenge for over a decade. Locarnini, Hatzakis, Chen, and
Lok, provide a worldwide perspective of the challenges that faces
hepatitis B virus (HBV) infection; which, unlike hepatitis C, has
been a controllable disease with effective drugs and vaccine for
a long time. They explore the potential impact of migration from
countries with high prevalence rates to those countries with low
rates of HBV infection. They then suggest that in order to eradi-
cate HBV, a world-view is necessary and the recent establishment
of the World Health Organisation Global Hepatitis Program pro-
vides a framework for global action. Lessons learnt from HBV pro-
grammes are providing guidance to the treatment of hepatitis C.
Manns, Lohse, and Vergani, who have helped change the
landscape of autoimmune hepatitis (AIH) pathogenesis and treat-
ments, make an extremely reasoned and potentially achievableS2 Journal of Hepatology 20target of avoiding the need for liver transplantation for this indi-
cation. They analyze the key developments in the understanding
and treatment of AIH over the past 50 years and also provide an
insight into how the understanding of the molecular and cellular
pathogenesis of AIH will lead to newer therapies allowing us to
achieve the stated aim.
Acute liver failure (ALF) is probably the most devastating and
dramatic liver disease that a Hepatologist can be called upon to
manage. The team led by Williams, Wendon, Bernal, Lee, and
Larsen, all innovators who have led the area over the past
30 years, explore the notion that ALF will indeed be a curable dis-
ease in the next 10 years. They argue that mortality rates for ALF
are declining rapidly and that with simple, non-speciﬁc mea-
sures, deaths from intracranial hypertension has become rare.
They think that the availability of liver support devices will help
in attaining this aim but also point to a focus on meticulous and
early management of this condition in partnership with expert
units. Better understanding of liver injury will allow the use of
novel interventions, which will prevent the occurrence of ALF.
Cirrhosis is by far the biggest immediate cause of mortality
from liver disease. Bosch, Groszmann, and Shah, all individuals
who made seminal observations and contributed enormously to
the successes in the ﬁeld of portal hypertension, focus on how
paradigm changes in disease pathogenesis are leading to further
changes in the management of portal hypertension. Mortality
rates from variceal bleeding have reduced by more than 5 times
in the past 30 years. They suggest that the next horizons are to
focus attention to intrahepatic resistance and angiogenesis as
potential therapeutic targets. The article by Arroyo, Moreau,
Jalan, and Ginès, all individuals who have helped deﬁne the syn-
drome, make a huge statement that ‘the discovery that acute on
chronic liver failure (ACLF) is a distinct syndrome will re-clas-
sify cirrhosis’. They argue that ACLF is a complex syndrome,
prevalent, affecting up to 30% of cirrhotic patients admitted to
the hospital, is distinct from decompensated cirrhosis, has a dis-
tinct diagnostic and prognostic criteria and is associated with
high rates of mortality. Pathophysiologically, the syndrome is
characterized by systemic inﬂammation pointing to potentially
new targets of therapy. The authors suggest that knowledge in
ACLF is at a point where it is possible to perform informed clinical
trials. European, American and Asian consortia have been formed
to study this syndrome.
Hepatocellular carcinoma (HCC) is increasing at an astonish-
ing rate and is one of the major causes of mortality in liver dis-
ease patients. The article by Bruix, Han, Gores, Llovet, and
Mazzaferro, brings together the leaders in HCC from all over
the world to address current issues, pointing to the fact that this
is an heterogeneous disease that requires a personalized
approach. They explore the huge advances that have been made
to the lives of patients with HCC, with distinct options for cure
of patients with resection, transplantation and radiological
approaches. They point to the massive expansion of the knowl-
edge in the ﬁeld, the increasing interest from industry and a
favorable regulatory environment as the key elements that will
drive even more effective and focused approaches to treatment.
Liver transplantation has revolutionized the management of
patients with liver failure but is limited by the availability of
organs and the associated costs. As the liver has an amazing
capacity to regenerate, temporary support with cells rather than
a whole organ would sufﬁce. Also, patients who are often
transplanted for metabolic diseases can survive with cell15 vol. 62 j S1–S3
Table 2. The top 10 cited original papers in the Journal of Hepatology; 1984–2014. Source of citations: Scopus. Courtesy, Joël Walicki; Journal of Hepatology Editorial
ofﬁce.
Authors Title Year of 
publication
No. of 
citations
Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, 
Gudat F, …, Thaler H
Histological grading and staging of chronic hepatitis 1995 2672
Perz JF, Armstrong GL, Farrington LA, Hutin YJF, 
Bell BP
The contributions of hepatitis B virus and hepatitis 
C virus infections to cirrhosis and primary liver 
cancer worldwide
2006 713
Piccinino F, Sagnelli E, Pasquale G, Giusti G, Battocchia A, 
Bernardi M, …, Zivelonghi P
Complications following percutaneous liver biopsy. A 
multicentre retrospective study on 68,276 biopsies
1986 629
Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, 
Rayón M, …, Wright TL
HCV-related fibrosis progression following liver 
transplantation: Increase in recent years
2000 567
Soto B, Sánchez-Quijano A, Rodrigo L, Olmo JAD, García-
Bengoechea M, Hernández-Quero J, …, Lissen E
Human immunodeficiency virus infection modifies the 
natural history of chronic parenterally-acquired hepatitis 
C with an unusually rapid progression to cirrhosis
1997 539
Rates and risk factors of liver fibrosis progression in 
patients with chronic hepatitis C
2001 489Poynard T, Ratziu V, Charlotte F, Goodman Z, 
McHutchison J, Albrecht J
Colloredo G, Guido M, Sonzogni A, Leandro G Impact of liver biopsy size on histological evaluation 
of chronic viral hepatitis: the smaller the sample, 
the milder the disease
2003 459
Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Malé P-J, 
Mentha G, …, Negro F
Hepatocyte steatosis is a cytopathic effect of 
hepatitis C virus genotype 3
2000 423
Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, 
Hasegawa K, Miyagawa S, …, Makuuchi M
Risk factors contributing to early and late phase 
intrahepatic recurrence of hepatocellular carcinoma 
after hepatectomy
2003 420
Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, 
Tamaki S, …, Tanikawa K
Therapeutic effects of restricted diet and exercise in 
obese patients with fatty liver
1997 410
JOURNAL OF HEPATOLOGYtransplantation rather than the whole organ. It is with this in
mind that cell transplantation as an alternative to liver trans-
plantation is being developed. Forbes, Gupta, and Dhawan,
who have led the ﬁeld of translational research in liver cell thera-
pies provide an excellent update and explore the current evi-
dence for various types of cell transplantation. They suggest
that utilization of stem cells offers signiﬁcant hope for producing
suitable liver cells of clinical interest for transplantation. Adams,
Sanchez-Fueyo, and Samuel, combine their very different exper-
tise in clinical and experimental liver transplantation to explore
the issues around inducing tolerance, which would reduce the
need to immunosuppression with calcineurins. They provide an
excellent overview of where we are and develop a roadmap to
clinical translation of immune tolerance in liver transplantation.
The idea for this supplement was conceived and developed by
the current and previous Editors or their representatives. I am
therefore very grateful to Prof. Roger Williams, Prof. Gustav
Paumgartner, Prof. Vicente Arroyo, Prof. Pere Ginès, Prof.
Massimo Colombo, and Prof. Didier Samuel for their fantastic
ideas and help in putting this supplement together. I would like
to thank the EASL Governing Board and the Senior Editors of
the current Editorial team for reﬁning the ideas and supporting
this endeavor. Of course, a huge vote of thanks is due to the many
authors of the excellent articles in this supplement. We thought a
lot about putting the leaders in individual ﬁelds to co-author arti-
cles understanding full well that this was going to be difﬁcult
given their individual lines of thought and their incredibly busy
schedules. Therefore, I admire and acknowledge the enormous
contribution of the Editorial team led by Joël Walicki, in produc-
ing this supplement. I invite you, the reader to celebrate 30 years
of the Journal of Hepatology and enjoy this supplement. TheJournal of Hepatology 20Journal of Hepatology has come a long way from its humble begin-
nings in 1984, reaching its highest impact factor, 10.4, which is a
fantastic achievement of the past Editors, Associate Editors,
reviewers, authors and readers. In order to celebrate our most
highly cited-authors, we have enumerated the highest cited
‘original’ papers published in the Journal of Hepatology in Table 2.
Finally, let us not forget the patients with liver disease. All the
research we perform and publish are inspired by them, involves them
and ultimately is for them!Conﬂict of interest
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